Answers are grounded in this paper and cite their sources.
This is a letter to the editor discussing a recent article on bleeding risk in patients with atrial fibrillation treated with dabigatran.
To the Editor We read with interest the recent article by Hernandez et al1 regarding bleeding risk in patients with atrial fibrillation treated with dabigatran. This work contributes to the ongoing debate regarding optimal anticoagulant use in patients with atrial fibrillation.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: